Latest Administration News

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.

Next Science Limited has applied for voluntary delisting from the ASX following the sale of nearly all its assets to OSARTIS GmbH. The company proposes a capital return to shareholders and intends to commence winding up after delisting.

Lefroy Exploration has made a strong start at its Lucky Strike Gold Mine near Kalgoorlie, with pre-strip mining well underway and first ore haulage scheduled for early 2026. The company is fully funded and poised to begin toll milling in February, marking a significant step toward production.

Income Asset Management has secured a $2 million unsecured debt facility at 15% interest to strengthen liquidity during the quieter Christmas period while awaiting insurance claim outcomes related to a recent fraud event.

The Northern Finland Administrative Court has overturned Kingsrose Mining’s exploration permit for the Penikat Project due to procedural errors by the regulator, delaying planned drilling until at least April 2026. Kingsrose remains confident in the project’s long-term potential despite the setback.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

Eminence Minerals has concluded its Supreme Court hearing challenging the recognition of two Aboriginal heritage sites on its Hamersley Iron Ore Project land, with a court decision expected in early 2026.

Assetora Limited has obtained a Supreme Court injunction restraining external receivers, allowing its directors to maintain control while agreeing on payments to noteholders.

Sarytogan Graphite Limited updates investors on its $5 million capital raising, highlighting regulatory approval delays but confirming near-term funding to advance its key graphite project.

PYC Therapeutics reports positive safety outcomes from the initial phase of its clinical trial for PYC-003, a promising treatment for Polycystic Kidney Disease. The drug was well tolerated in healthy volunteers, paving the way for patient dosing and further trials.

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.